{"id":238200,"date":"2024-05-22T10:29:27","date_gmt":"2024-05-22T08:29:27","guid":{"rendered":"https:\/\/fefac.cat\/empresarial\/?p=238200"},"modified":"2024-05-23T12:13:50","modified_gmt":"2024-05-23T10:13:50","slug":"aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea","status":"publish","type":"post","link":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/","title":{"rendered":"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica europea"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Les complicacions en l&#8217;acc\u00e9s a medicaments gen\u00e8rics \u00e9s una de les conseq\u00fc\u00e8ncies de la reforma de la regulaci\u00f3 farmac\u00e8utica europea<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">L&#8217;Associaci\u00f3 Espanyola de Medicaments Gen\u00e8rics (AESEG) considera urgent la r<strong>evisi\u00f3 de la normativa sobre la seguretat de prove\u00efment que es recull en la nova legislaci\u00f3 farmac\u00e8utica europea<\/strong>. Segons AESEG \u00e9s impossible per als titulars de les autoritzacions de comercialitzaci\u00f3 (TACs) de medicaments gen\u00e8rics, amb portafolis amplis de f\u00e0rmacs, mantenir<strong> plans de prevenci\u00f3 de desprove\u00efment<\/strong> per a tots els seus medicaments.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La patronal proposa que aquests procediments se centrin en una<strong> selecci\u00f3 de medicaments cr\u00edtics<\/strong>. Tamb\u00e9 que s&#8217;aprofiti el <strong>Sistema Espanyol de Verificaci\u00f3 de Medicaments<\/strong> (SEVeM) per a gestionar els estocs de f\u00e0rmacs i prevenir desprove\u00efments de manera efectiva.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tot aix\u00f2, es va exposar en la taula de debat <strong>\u2018Nova legislaci\u00f3 europea: impacte en la ind\u00fastria farmac\u00e8utica d&#8217;Espanya\u2019,<\/strong> celebrada en el marc del 42\u00e8 Symposium de l&#8217;Associaci\u00f3 Espanyola de Farmac\u00e8utics de la Ind\u00fastria (AEFI). Referent a aix\u00f2, la Pharmaceutical Affairs Head de Sandoz Ib\u00e8ria, Gr\u00e0cia Esperons, va explicar que, en el cas dels <strong>antimicrobians<\/strong>,<strong> la patronal s&#8217;oposa als incentius <\/strong>a la innovaci\u00f3 proposats per la Comissi\u00f3 Europea i recolzats pel Parlament Europeu, pel seu <strong>impacte negatiu en l&#8217;acc\u00e9s a medicaments gen\u00e8rics<\/strong>. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AESEG dona suport a la <strong>modulaci\u00f3 d&#8217;incentius<\/strong>, sempre que ofereixin claredat i predictibilitat per a la comercialitzaci\u00f3 de medicaments gen\u00e8rics. Per\u00f2 adverteix que <strong>estendre excessivament els per\u00edodes de patents<\/strong> <strong>pot incrementar els costos sanitaris<\/strong>. Per a la patronal, el total de protecci\u00f3 <strong>no ha de superar la situaci\u00f3 actual d&#8217;un m\u00e0xim d&#8217;11 anys<\/strong>. Assenyala tamb\u00e9 com a exemple el cas d&#8217;Espanya, on ampliar un any la protecci\u00f3 de les 15 mol\u00e8cules blockbuster pr\u00f2ximes a perdre patent, tindria un impacte en els costos d&#8217;assist\u00e8ncia sanit\u00e0ria de m\u00e9s de dos mil milions d&#8217;euros.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Podeu llegir la not\u00edcia completa <a href=\"https:\/\/www.aeseg.es\/es\/notas-de-prensa-2024\/3479-aeseg-reivindica-normas-en-la-nueva-legislacion-farmaceutica-europea-que-aseguren-el-abastecimiento-de-medicamentos\">aqu\u00ed<\/a>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Font<\/strong>: AESEG<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L&#8217;Associaci\u00f3 Espanyola de Medicaments Gen\u00e8rics (AESEG) considera urgent la revisi\u00f3 de la normativa sobre la seguretat de prove\u00efment que es recull en la nova legislaci\u00f3 farmac\u00e8utica europea. Segons AESEG \u00e9s impossible per als titulars de les autoritzacions de comercialitzaci\u00f3 (TACs) de medicaments gen\u00e8rics, amb portfolios amplis de f\u00e0rmacs, mantenir plans de prevenci\u00f3 de desprove\u00efments per a tots els seus medicaments.\u00a0<\/p>\n","protected":false},"author":5,"featured_media":238202,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"off","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2066,10,11,12,13,14,15,294,101],"tags":[68,85,711,1156,2789,2817,2818],"class_list":["post-238200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-categoria-actualitat","category-empresarials","category-fefac","category-afb","category-afet","category-afell","category-agfe","category-politica-sanitaria","category-sanitaria","tag-aeseg","tag-fefac","tag-farmaceutics","tag-farmacies","tag-medicaments-generics","tag-legislacio-farmaceutica-europea","tag-aefi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica<\/title>\n<meta name=\"description\" content=\"Complicacions en l&#039;acc\u00e9s a medicaments gen\u00e8rics \u00e9s una de les conseq\u00fc\u00e8ncies de la reforma de la regulaci\u00f3 farmac\u00e8utica europea.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica\" \/>\n<meta property=\"og:description\" content=\"Complicacions en l&#039;acc\u00e9s a medicaments gen\u00e8rics \u00e9s una de les conseq\u00fc\u00e8ncies de la reforma de la regulaci\u00f3 farmac\u00e8utica europea.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/\" \/>\n<meta property=\"og:site_name\" content=\"FEFAC\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-22T08:29:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-23T10:13:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/05\/unnamed-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"480\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"lgallardo@fefac.cat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"lgallardo@fefac.cat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/\"},\"author\":{\"name\":\"lgallardo@fefac.cat\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/1fd062d4deaeeca8c3e2fce65b312ce9\"},\"headline\":\"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica europea\",\"datePublished\":\"2024-05-22T08:29:27+00:00\",\"dateModified\":\"2024-05-23T10:13:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/\"},\"wordCount\":349,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/unnamed-1.jpg\",\"keywords\":[\"AESEG\",\"FEFAC\",\"farmac\u00e8utics\",\"farm\u00e0cies\",\"medicaments gen\u00e8rics\",\"legislaci\u00f3 farmac\u00e8utica europea\",\"AEFI\"],\"articleSection\":[\"Actualitat\",\"Empresarials\",\"FEFAC\",\"AFB\",\"AFET\",\"AFELL\",\"AGFE\",\"Pol\u00edtica sanit\u00e0ria\",\"Sanit\u00e0ria\"],\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/\",\"name\":\"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/unnamed-1.jpg\",\"datePublished\":\"2024-05-22T08:29:27+00:00\",\"dateModified\":\"2024-05-23T10:13:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/1fd062d4deaeeca8c3e2fce65b312ce9\"},\"description\":\"Complicacions en l'acc\u00e9s a medicaments gen\u00e8rics \u00e9s una de les conseq\u00fc\u00e8ncies de la reforma de la regulaci\u00f3 farmac\u00e8utica europea.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#primaryimage\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/unnamed-1.jpg\",\"contentUrl\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/unnamed-1.jpg\",\"width\":640,\"height\":480},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica europea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#website\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/\",\"name\":\"FEFAC\",\"description\":\"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/#\\\/schema\\\/person\\\/1fd062d4deaeeca8c3e2fce65b312ce9\",\"name\":\"lgallardo@fefac.cat\",\"url\":\"https:\\\/\\\/fefac.cat\\\/empresarial\\\/author\\\/lucia-2\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica","description":"Complicacions en l'acc\u00e9s a medicaments gen\u00e8rics \u00e9s una de les conseq\u00fc\u00e8ncies de la reforma de la regulaci\u00f3 farmac\u00e8utica europea.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/","og_locale":"ca_ES","og_type":"article","og_title":"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica","og_description":"Complicacions en l'acc\u00e9s a medicaments gen\u00e8rics \u00e9s una de les conseq\u00fc\u00e8ncies de la reforma de la regulaci\u00f3 farmac\u00e8utica europea.","og_url":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/","og_site_name":"FEFAC","article_published_time":"2024-05-22T08:29:27+00:00","article_modified_time":"2024-05-23T10:13:50+00:00","og_image":[{"width":640,"height":480,"url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/05\/unnamed-1.jpg","type":"image\/jpeg"}],"author":"lgallardo@fefac.cat","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"lgallardo@fefac.cat","Temps estimat de lectura":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#article","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/"},"author":{"name":"lgallardo@fefac.cat","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/1fd062d4deaeeca8c3e2fce65b312ce9"},"headline":"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica europea","datePublished":"2024-05-22T08:29:27+00:00","dateModified":"2024-05-23T10:13:50+00:00","mainEntityOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/"},"wordCount":349,"commentCount":0,"image":{"@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/05\/unnamed-1.jpg","keywords":["AESEG","FEFAC","farmac\u00e8utics","farm\u00e0cies","medicaments gen\u00e8rics","legislaci\u00f3 farmac\u00e8utica europea","AEFI"],"articleSection":["Actualitat","Empresarials","FEFAC","AFB","AFET","AFELL","AGFE","Pol\u00edtica sanit\u00e0ria","Sanit\u00e0ria"],"inLanguage":"ca","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/","url":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/","name":"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica","isPartOf":{"@id":"https:\/\/fefac.cat\/empresarial\/#website"},"primaryImageOfPage":{"@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#primaryimage"},"image":{"@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#primaryimage"},"thumbnailUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/05\/unnamed-1.jpg","datePublished":"2024-05-22T08:29:27+00:00","dateModified":"2024-05-23T10:13:50+00:00","author":{"@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/1fd062d4deaeeca8c3e2fce65b312ce9"},"description":"Complicacions en l'acc\u00e9s a medicaments gen\u00e8rics \u00e9s una de les conseq\u00fc\u00e8ncies de la reforma de la regulaci\u00f3 farmac\u00e8utica europea.","breadcrumb":{"@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/"]}]},{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#primaryimage","url":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/05\/unnamed-1.jpg","contentUrl":"https:\/\/fefac.cat\/empresarial\/wp-content\/uploads\/2024\/05\/unnamed-1.jpg","width":640,"height":480},{"@type":"BreadcrumbList","@id":"https:\/\/fefac.cat\/empresarial\/aeseg-reclama-normes-en-la-nova-legislacio-farmaceutica-europea\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fefac.cat\/empresarial\/"},{"@type":"ListItem","position":2,"name":"AESEG reclama normes en la nova legislaci\u00f3 farmac\u00e8utica europea"}]},{"@type":"WebSite","@id":"https:\/\/fefac.cat\/empresarial\/#website","url":"https:\/\/fefac.cat\/empresarial\/","name":"FEFAC","description":"Federaci\u00f3 d&#039;Associacions de Farm\u00e0cies de Catalunya","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fefac.cat\/empresarial\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/fefac.cat\/empresarial\/#\/schema\/person\/1fd062d4deaeeca8c3e2fce65b312ce9","name":"lgallardo@fefac.cat","url":"https:\/\/fefac.cat\/empresarial\/author\/lucia-2\/"}]}},"_links":{"self":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/238200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/comments?post=238200"}],"version-history":[{"count":7,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/238200\/revisions"}],"predecessor-version":[{"id":238210,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/posts\/238200\/revisions\/238210"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media\/238202"}],"wp:attachment":[{"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/media?parent=238200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/categories?post=238200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fefac.cat\/empresarial\/wp-json\/wp\/v2\/tags?post=238200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}